Indications for imatinib mesylate therapy and clinical management.
about
Imatinib for treating newly diagnosed chronic myeloid leukemia patientsImatinib for treating patients with chronic myelogeneous leukemiaSystemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and managementEvaluation of Cytopenias Occurring in Imatinib Treated Chronic Myeloid Leukemia (CML) Patients.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort studyPeriorbital edema secondary to imatinib mesylate.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes.A review of novel therapies for melanoma.A gist of gastrointestinal stromal tumors: A review.A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancerImproving access to care in low and middle-income countries: institutional factors related to enrollment and patient outcome in a cancer drug access program.Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury.C-kit expression in human osteosarcoma and in vitro assaysPTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancerFeasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.Sarcomas and pharmacogenetics.A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growthA multidisciplinary approach for the treatment of GIST liver metastasisChronic Myeloid Leukaemia in The 21st Century.Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor.Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group studyKinase drug discovery approaches in chronic myeloproliferative disorders.Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients.Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib.Advanced or metastatic gastrointestinal stromal tumors: systemic treatment options.Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies.Targeting Melanoma with Cancer-Killing Viruses.A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.Generalized lichenoid drug eruption associated with imatinib mesylate therapy.Urinary Dopamine as a Potential Index of the Transport Activity of Multidrug and Toxin Extrusion in the Kidney.The teratogenic effects of imatinib mesylate on rat fetuses.Imatinib causing drug rash with eosinophilia and systemic symptoms: A rare cutaneous reaction.Soft tissue sarcoma clinical practice guidelines in oncology.Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins.Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry.
P2860
Q24186877-E0CD54D2-158C-4A6E-B282-127211EBEB16Q24241730-76D64A62-AFB6-4599-B48F-D4F11E595884Q26830695-8D6227EE-B8D3-4D6B-96B7-78FD10A9C9A0Q33395597-76BC6A19-9185-48D6-BFC7-EC866047DA29Q33410375-16FCB86F-2FCD-4E5D-9BCE-D7C89F482549Q33756542-CF8C0EE6-915E-471B-8B23-A69FEC40BA84Q33867897-07CD2A44-80EE-4FCB-BCB3-FA6372E300F2Q33921067-A19C16F3-4FEC-4265-AAAC-328F5EE80968Q34389029-ECAEE28F-7FA4-40D3-9973-E8CD9D6532B4Q34424764-092640D5-4417-4AF2-BE4E-E8FD8628538EQ34654203-1C5BB849-544D-4EF7-A80A-D68772C4D9AAQ34683885-2E0EF781-012A-4CC1-8E98-1838E340E695Q34929859-D7E25D4C-75F9-4037-B36F-FE27DA507386Q35115797-DB901965-C105-4F58-BB53-D63B5ACEE66DQ35577872-24CE89B0-E7F8-4917-B77D-93F8114CC381Q35952035-F65FCBD7-5F45-421F-AEA2-8FA3534FBACCQ36194549-A496F474-657B-46E0-9CFC-1CAC360CDC0EQ36249224-15DED159-0AEF-4E8C-AF85-86FB79E55B7FQ36352562-EFF67D32-2EE3-4FE0-9138-693AD64364BEQ36699413-CC9FCDDE-5842-4269-8783-370645862A06Q36731265-6524B103-C66F-4493-96D3-725FFEB076C5Q37367438-0C4808B3-02D3-4311-A152-A1BE540E373FQ37385584-46A73606-CD7D-485B-88DE-647B0168C801Q37412290-A64F1751-1724-400F-9EC9-B66D89F90323Q37472874-A125FBC0-096A-4F7C-98A8-8AB418675538Q37729245-86CE1E0E-DEBF-4AF8-9438-9F67A655CBF1Q37930709-B0CCB272-A1CC-46DA-969F-16BE498A8E31Q37954205-0CA5FC25-A5AD-492A-833F-15FC62E6148AQ38101103-298F9FF3-2ABD-487A-B891-CF860C0C5305Q38112804-5B2270D2-EC12-4CFF-A2C6-A062B7051F6EQ38676416-23670284-136E-4D73-A408-0AE863BF155AQ38729029-975900D2-1CBF-4192-B687-DA856E92DE66Q39341609-8BD2F1FF-95F3-4774-9BDD-CCF74FE10058Q40952339-C442D182-73BD-4578-A8BD-D4C09A185293Q41680312-5DA08293-7D1A-488F-8C81-00506FDBAE07Q42135221-E1CA956E-86AE-4CAF-A4E9-7FD39A629B2CQ42542953-4CA89406-655B-4035-95E2-C783B9C2DF22Q46599080-89CE7DB1-5CCC-4E62-A277-246706587678Q47895958-8993FD14-BCC5-453C-924A-D9F4AE8DC99EQ51336894-248C6270-6002-4A48-9C48-9ABA978A4FA8
P2860
Indications for imatinib mesylate therapy and clinical management.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Indications for imatinib mesylate therapy and clinical management.
@ast
Indications for imatinib mesylate therapy and clinical management.
@en
type
label
Indications for imatinib mesylate therapy and clinical management.
@ast
Indications for imatinib mesylate therapy and clinical management.
@en
prefLabel
Indications for imatinib mesylate therapy and clinical management.
@ast
Indications for imatinib mesylate therapy and clinical management.
@en
P1433
P1476
Indications for imatinib mesylate therapy and clinical management.
@en
P2093
François Guilhot
P304
P356
10.1634/THEONCOLOGIST.9-3-271
P577
2004-01-01T00:00:00Z